Secondary Logo

Journal Logo

Features of a Chinese family with cerebral cavernous malformation induced by a novelCCM1gene mutation

WANG, Xue; LIU, Xue-wu; Lee, Nora; LIU, Qi-ji; LI, Wen-na; HAN, Tao; WEI, Kun-kun; QIAO, Shan; CHI, Zhao-fu

doi: 10.3760/cma.j.issn.0366-6999.20130590
Original article
Free

Background Familial cerebral cavernous malformations (CCMs), characterized by hemorrhagic stroke, recurrent headache and epilepsy, are congenital vascular anomalies of the central nervous system. Familial CCMs is an autosomal dominant inherited disorder and three CCM genes have been identified. We report a Chinese family with CCMs and intend to explore clinical, pathological, magnetic resonance imaging (MRI) features and pathogenic gene mutation of this family.

Methods Totally 25 family members underwent brain MRI examination and clinical check. Two patients with surgical indications had surgical treatment and the specimens were subjected to histopathological and microstructural examination. In addition, polymerase chain reaction (PCR) and direct sequencing were performed with genomic DNA extracted from 25 family members' blood samples for mutation detection.

Results Brain MRI identified abnormal results in seven family members. All of them had multiple intracranial lesions and four cases had skin cavernous hemangioma. T2-weighted sequence showed that the lesions were typically characterized by an area of mixed signal intensity. Gradient-echo (GRE) sequence was more sensitive to find microcavernous hemangiomas. There was a wide range in the clinical manifestations as well as the age of onset in the family. The youngest patient was an 8-year-old boy with least intracranial lesions. Histopathological and microstructural examination showed that CCMs were typically discrete multi-sublobes of berry-like lesions, with hemorrhage in various stages of illness evolution. They were formed by abnormally enlarged sinusoids and the thin basement membranes. A novel T deletion mutation in exon 14 of CCM1 gene was identified by mutation detection in the seven patients. But unaffected members and healthy controls did not carry this mutation.

Conclusions The clinical manifestations were heterogenic within this family. We identified a novel mutation (c.1396delT) was the disease-causing mutation for this family and extended the mutational spectrum of CCMs.

Department of Neurology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China (Wang X, Liu XW, Li WN, Han T, Wei KK, Qiao S and Chi ZF)

Department of Neurology, Hartford Hospital, Hartford, Connecticut 06106, USA (Lee N)

Department of Medical Genetics, Key Laboratory for Experimental Teratology of the Ministry of Education, Shandong University School of Medicine, Jinan, Shandong 250012, China (Liu QJ)

Correspondence to: Dr. LIU Xue-wu, Department of Neurology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China (Tel: 86–531–82166166. Email: snlxw1966@yahoo.com.cn)

This study was supported by grants from the National Natural Science Foundation of China (No. 81171071) and the Natural Science Foundation of Shandong Province (No. ZR2010HM052).

(Received February 28, 2013)

Edited by JI Yuan-yuan

Cerebral cavernous malformations (CCMs) is a common form of vascular anomaly with abnormally enlarged capillary cavities that are prone to rupture causing hemorrhagic stroke, accounting for 5%-15% of all vascular malformations in the central nervous system.1–3 Cases can occur sporadically or be inherited in an autosomal dominant fashion with incomplete penetrance.4 Familial CCMs have been due to mutations at 3 loci identified by linkage analysis and positional cloning: CCM1 (OMIM 116860) on 7q21 that is more responsible for CCMs,5–7CCM2 (OMIM 603284) on 7p13, and CCM3 (OMIM 603285) on 3q26,8 which are less commonly associated with this disorder.9,10 So far, the reported familial CCMs have been mainly described in the Mexican/Hispanic population, demonstrating founder effect in this community.11–13 However, there are a few Chinese families with CCMs having been referred during recent decade.14–16 We here report a Chinese family with CCMs due to a novel mutation in exon 14 of CCM1 gene. Our study expands the spectrum of mutations in CCM1 linked to CCMs and implies the potential implications in the prenatal counseling or genetic diagnosis for this family in the future.

Back to Top | Article Outline

METHODS

Participants

We studied a 25-member Chinese family with CCMs, involving seven patients (five male and two female). The index person was a 50-year-old man with hemorrhagic stroke in the left basal ganglia. After acquiring informed consent following the protocols approved by the local ethics committee, all of the participants underwent detailed medical history, clinical evaluation highlighting results of neurological, dermatological, and ophthalmological examinations, and mutation analysis.

Back to Top | Article Outline

Brain magnetic resonance imaging (MRI) acquisition

Participants completed a clinical brain MRI on 1.5 Tesla GE Signa and Genesis systems (Siemens, Germany), including axial and coronal T1-weighted images, axial and coronal T2-weighted images, fluid-attenuated inversion recovery, diffusion-weighted images, spin echo sequence and gradient echo sequence. The MRI slice/gap thickness was 6.0/0.5 mm, and the matrix size was 224 × 256 for all sequences. Experienced neuroradiologists reviewed the brain MRI images.

Back to Top | Article Outline

Brain histopathological and ultrastructural examinations

Two patients with serious hemiplegia had surgical treatment and histopathologic and ultrastructural examinations were performed on the specimens.

Back to Top | Article Outline

Blood samples

Blood samples were obtained from the 25 family members with their informed consent and were added to ethylene diamine tetraacetic acid (EDTA). Genomic DNA was extracted from peripheral blood.

Back to Top | Article Outline

Mutation detection

PCR was performed to amplify all of the coding exons of the three CCM genes (CCM1, CCM2 and CCM3). The primers were designed to encompass each exon and its flanking exon-intronic splice sites. Primers sequences were shown in Table 1. PCR was conducted under the following conditions: pre-denaturation at 94°C for 5 minutes, 35 cycles of denaturation at 95°C for 30 seconds, annealing at suitable temperature (Table 1) for 30 seconds, extension at 72°C for 30 seconds, and final extension at 72°C for 5 minutes. PCR amplified products underwent 1.5% agarose gel electrophoresis and were then analyzed by direct sequencing on ABI sequencer (Applied Biosystems Inc., USA). One of the amplification primers was used as a sequencing primer, and the sequencing results were analyzed by a BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi). DNA fragments with mutations were cloned into a PMD-18T vector (Takara, Japan) and transformed into E.coli bacterium. The identified variation in the proband was examined in other affected and unaffected family members as well as 100 healthy controls from China.

Table 1

Table 1

Back to Top | Article Outline

RESULTS

Clinical features

The family pedigree is shown in Figure 1. The index person is a 50-year-old man with sudden onset of right limbs weakness and slurred speech. Neurological examination showed sensory and movement disturbance in right limbs. Dermatological examination demonstrated a 3 cm × 2 cm irregular bluish violet mass with protruding vessels in the lateral malleolus of his right foot (Figure 2).

Figure 1.

Figure 1.

The proband's father died of hemorrhagic stroke at the age of 76 years and could be considered as a patient with CCMs. All 25 remaining living family members took part in the investigation. There was a wide range in clinical manifestations as well as the age of onset within the family. Three patients presented with recurrent headache, three with hemiplegia, one with seizure, one with difficulty in swallowing or dysdipsia and one with hemianopia. Four patients with skin cavernous hemangioma had CCMs. Ophthalmological examination showed no abnormalities.

Back to Top | Article Outline

Brain MRI or CT

The index patient's brain CT (Figure 3A) showed a hemorrhagic and calcified lesion in the left basal ganglia. Further brain MRI (Figure 3B-F) revealed multiple CCMs in the cerebral hemisphere, cerebellar and brainstem. MRI is the most sensitive modality for the diagnosis of CCMs. With T2-weighted sequences, the lesions are typically characterized by an area of mixed signal intensity. Gradient-echo (GRE) sequence MRI could find microcavernous hemangiomas with a central reticulated core and a peripheral rim of decreased signal intensity related to deposition of hemosiderin.

Figure 3.

Figure 3.

Other than the proband, six patients were identified by brain MRI (four male and two female), aged from 8–79-years old (mean age of 35.8 years). All of them displayed multiple CCMs. The number of intracranial lesions ranged from 18 to 49, and size from 0.2–5.0 cm.

Back to Top | Article Outline

Brain histopathological and ultrastructural features

Two patients' pathological examinations of the excised tissues confirmed CCMs (Figure 4). The lesions are berry-like hemangiomas, with typically discrete sublobes, owing to hemorrhage in various stages during illness evolution. Cavernous angiomas are composed of abnormally enlarged sinusoids. Hemorrhagic residua within the lesions are commonly seen (Figure 4A). Under an ultramicroscope, it was found that the basement membranes of sinusoids become thicker and looser. Parts of them are layered. And many disorganized collagen bundles exist in it. Sinusoids are formed by a monolayer endothelial cell and a large number of red blood cells are seen in the cavities (Figure 4B).

Figure 4.

Figure 4.

Back to Top | Article Outline

Genetic analysis

Screening of the 16 coding exons (exons 5–20) and flanking sequences of CCM1 gene revealed a heterozygous T deletion in exon 14 (c.1396delT) of the index patient (Figure 5A and 5B). All of the patients but no unaffected family members or unrelated healthy controls carried the same mutation (Figure 5C). This frameshift mutation was predicted to cause a premature translational termination signal at nucleotide (NT) 1481 to 1483, with a truncated Krev interaction trapped-1 (KRIT1) protein of 493 amino acids.

Figure 5.

Figure 5.

Back to Top | Article Outline

DISCUSSION

The most common presenting symptoms of CCMs include hemorrhagic stroke, seizure, recurrent headache, and focal neurological deficits.17–19 Patients' symptoms are clinical heterogeneity within or between families affected with CCMs. Many asymptomatic family members had obvious intracranial lesions revealed by brain MRI, but were clinically silent. It could be due to incomplete penetrance.20 Apart from the diversity of symptoms, the age of onset and severity, also varied to a large extent.21 The reasons for this variability are unclear, but there is a strong correlation between the age of patients and the number of lesions: the younger, the less lesions.22 In the family, it is also confirmed by the youngest 8-year-old boy with the least lesions comparing with the other six patients.

MRI is the most sensitive modality for the diagnosis of CCMs.23 GRE sequence could find micro-cavernous hemangiomas with a central reticulated core and a peripheral rim of decreased signal intensity related to the deposition of hemosiderin. The excised intracranial lesions of two patients have been performed on pathological examinations. CCMs are typically discrete multi-sublobes berry-like lesions that contain hemorrhage in various stages of illness evolution. The resected hemangiomas show abnormal ultrastructural pathological features. The recurrent embolization of CCMs has resulted in endothelial cells denudation. The thin walls of abnormal vessels, lacking significant subendothelial support, along with the rare tight junctions between endothelial cells, may contribute to the known propensity of CCMs for recurrent micro-hemorrhage.

Cerebral cavernous malformations can be both sporadic and familial. Almost half of CCMs cases are heriditory in nature and follow autosomal dominant trait with variable penetrance.24 However, approximately 60% of the sporadic cases of CCMs are demonstrated to be familial ones with identified familial mutations actually.25 Familial CCMs are more susceptible to have multiple intracranial lesions and is mainly distributed in Hispanic populations of Mexican descent. In our study, all the patients in this Chinese family had multiple intracranial lesions. Four patients with skin cavernous hemangioma all had CCMs. Gunel et al26 performed a linkage analysis in a Hispanicfamily and mapped the first gene CCM1 responsible for CCMs to 7q11.2-q21. And then they identified a strong founder effect that the identical haplotypes over a short segment of chromosome 7q existed in several unrelated Hispanic kindreds with FCCMs.11 However, this disorder is genetically heterogeneous and two additional genes have also been mapped on 7p15–13 (CCM2) and 3q25.2–27 (CCM3), respectively, which are less commonly associated with CCMs.8

CCM1 includes 16 coding exons and encodes Krev interaction trapped-1 (KRIT1) protein, a 736-amino acid microtubule-associated protein, containing two functional motifs: three putative ankyrin repeats and a C-terminal FERM domain. The protein plays an important regulatory role in angiogenesis by involvement in Rap1A (also known as Krev1)/Ras signal transduction pathways as well as in tumor suppression processes.27 In addition, KRIT1 is reported to interact with intergrin cytoplasmic domain-associated protein-1 (ICAP-1), which regulates cell adhesion processes and extracellular matrix (ECM) interactions by binding to the N-terminal region of KRIT1.28

To date, CCM1 mutations account for a large proportion of identified pathogenetic mutations of CCMs. Among the 135 CCM1 mutations, 43 are small deletions, 23 small insertions and 38 missense/nonsense mutations, 24 splicing mutations, three small indels, three gross deletions and one gross insertion/duplication. Most of these mutations were significantly more often clustered in the second half of the CCM1 gene.

Though familial CCMs are more common in the Mexican/ Hispanic population, there are a few studies performed in Chinese community in recent decade. Interestingly, all the reported CCMs mutations in Chinese families are in the CCM1 gene, including two deletion mutations,15,16 two missense mutations14,29 and one splicing mutation.30 Chen et al14 and Xu et al29 reported two point mutations in exon 19 (c.2835CT, p.Q698X) and exon14 (c.1298CG, p.S430X) of CCM1 gene, respectively, in three Chinese families with CCMs. Mao et al16 first found an AT deletion mutation in exon 13 (c.1292delAT), resulting in a truncated KRIT1 protein. In 2011, another deletion mutation in exon 12 of CCM1 gene (c.1197delCAAA) was also identified.15 Till now, there is only one splicing mutation of a GTA deletion at the acceptor splicing site of intron 9/exon 10 in CCM1, causing a truncated protein by creating a premature termination code at the 23rd amino acid downstream from the sequence alteration.30 It appears that CCM1, rather than CCM2 or CCM3, is likely to be the dominant pathogenic cause of familial CCMs in Chinese population. All of these mutations are located within the second half of CCM1 gene and predicted to produce a truncated KRIT1 protein, which is consistent with the international reports.6 We hypothesize a loss of function due to mutated gene which may produce unstable mRNA or proteins without function is the most likely pathogenetic mechanism of CCMs.

Our study here reports a novel mutation, deletion of a T in exon 14 (c.1396delT) of CCM1 gene, which also could result in a premature stop codon at the second half of CCM1, with a 493-amino acid truncated protein. The C-terminal mutations may remove ankyrin repeats and lose the recognition site Rap1A which interacts with KRIT1. However, these inferences are required to be validated in more Chinese familial CCMs or by further molecular biological research.

Back to Top | Article Outline

Acknowledgment:

We thank the patients and their families for their participation.

Back to Top | Article Outline

REFERENCES

1. Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg 1991; 75: 709-714.
2. Cavalcanti DD, Kalani MY, Martirosyan NL, Eales J, Spetzler RF, Preul MC. Cerebral cavernous malformations: from genes to proteins to disease. J Neurosurg 2012; 116: 122-132.
3. Moriarity JL, Wetzel M, Clatterbuck RE, Javedan S, Sheppard JM, Hoenig-Rigamonti K, et al. The natural history of cavernous malformations: a prospective study of 68 patients. Neurosurgery 1999; 44: 1166-1171; discussion 1172-1163.
4. Ng BH, Mulyadi E, Pereira JK, Ghedia S, Pinner J, Mowat D, et al. Familial cerebral cavernous haemangioma diagnosed in an infant with a rapidly growing cerebral lesion. Australas Radiol 2006; 50: 583-590.
5. Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M, et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005; 76: 42-51.
6. Cave-Riant F, Denier C, Labauge P, Cécillon M, Maciazek J, Joutel A, et al. Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with cerebral cavernous malformations. Eur J Hum Genet 2002; 10: 733-740.
7. Marchuk DA, Gallione CJ, Morrison LA, Clericuzio CL, Hart BL, Kosofsky BE, et al. A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics 1995; 28: 311-314.
8. Craig HD, Gunel M, Cepeda O, Johnson EW, Ptacek L, Steinberg GK, et al. Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Hum Mol Genet 1998; 7: 1851-1858.
9. D'Angelo R, Marini V, Rinaldi C, Origone P, Dorcaratto A, Avolio M, et al. Mutation analysis of CCM1, CCM2 and CCM3 genes in a cohort of Italian patients with cerebral cavernous malformation. Brain Pathol 2011; 21: 215-224.
10. Battistini S, Rocchi R, Cerase A, Citterio A, Tassi L, Lando G, et al. Clinical, magnetic resonance imaging, and genetic study of 5 Italian families with cerebral cavernous malformation. Arch Neurol 2007; 64: 843-848.
11. Gunel M, Awad IA, Finberg K, Anson JA, Steinberg GK, Batjer HH, et al. A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl J Med 1996; 334: 946-951.
12. Polymeropoulos MH, Hurko O, Hsu F, Rubenstein J, Basnet S, Lane K, et al. Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican-American descent. Neurology 1997; 48: 752-757.
13. Zhang J, Clatterbuck RE, Rigamonti D, Dietz HC. Mutations in KRIT1 in familial cerebral cavernous malformations. Neurosurgery 2000; 46: 1272-1279.
14. Chen DH, Lipe HP, Qin Z, Bird TD. Cerebral cavernous malformation: novel mutation in a Chinese family and evidence for heterogeneity. J Neurol Sci 2002; 196: 91-96.
15. Zhao Y, Xie L, Li P, Song J, Qu T, Fan W, et al. A novel CCM1 gene mutation causes cerebral cavernous malformation in a Chinese family. J Clin Neurosci 2011; 18: 61-65.
16. Mao Y, Zhao Y, Zhou LF, Huang CX, Shou XF, Gong JL, et al. A novel gene mutation (1292 deletion) in a Chinese family with cerebral cavernous malformations. Neurosurgery 2005; 56: 1149-1153; discussion 1149-1153.
17. Hsu PW, Chang CN, Tseng CK, Wei KC, Wang CC, Chuang CC, et al. Treatment of epileptogenic cavernomas: surgery versus radiosurgery. Cerebrovasc Dis 2007; 24: 116-121.
18. Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol 2007; 6: 237- 244.
19. Rabinstein AA, Tisch SH, McClelland RL, Wijdicks EF. Cause is the main predictor of outcome in patients with pontine hemorrhage. Cerebrovasc Dis 2004; 17: 66-71.
20. Gianfrancesco F, Cannella M, Martino T, Maglione V, Esposito T, Innocenzi G, et al. Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 691-695.
21. Belousova OB, Konovalov AN, Okishev DN, Sazonova OB, Shamov A. Hereditary cerebral cavernous malformations: analysis of 12 families. Zh Vopr Neirokhir Im N N Burdenko (Russian) 2011; 75: 34-47.
22. Labauge P, Laberge S, Brunereau L, Levy C, Tournier-Lasserve E. Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families. Lancet 1998; 352: 1892-1897.
23. Chi LY, Wang SH, Liu XW, Su LJ, Zhao XH, Wu W, et al. Familial cerebral cavernous malformation: features of clinical manifestation, pathology and imaging in a Chinese family. Cerebrovasc Dis 2008; 26: 206-208.
24. Lee ST, Choi KW, Yeo HT, Kim JW, Ki CS, Cho YD. Identification of an Arg35X mutation in the PDCD10 gene in a patient with cerebral and multiple spinal cavernous malformations. J Neurol Sci 2008; 267: 177-181.
25. Denier C, Labauge P, Bergametti F, Marchelli F, Riant F, Arnoult M, et al. Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 2006; 60: 550-556.
26. Gunel M, Awad IA, Anson J, Lifton RP. Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21. Proc Natl Acad Sci U S A 1995; 92: 6620-6624.
27. Laberge-le Couteulx S, Jung HH, Labauge P, Houtteville JP, Lescoat C, Cecillon M, et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999; 23: 189-193.
28. Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA. KRIT1 association with the integrin-binding protein ICAP1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum Mol Genet 2002; 11: 389-396.
29. Xu YL, Zhao JZ, Wu BQ, Zhong HH, Wang S, Heng WJ. A novel Krit-1 mutation in Han family with cerebral cavernous malformation. Chin J Pathol (Chin) 2003; 32: 220-225.
30. Ji BH, Qin W, Sun T, Feng GY, He L, Wang YJ. A novel deletion mutation in CCM1 gene (krit1) is detected in a Chinese family with cerebral cavernous malformations. J Genet Genomics 2006; 33: 105-110.
Keywords:

cavernous malformation; pathology; magnetic resonance imaging; CCM1; gene mutation; Chinese family

© 2013 Chinese Medical Association